186 related articles for article (PubMed ID: 28242632)
21. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
[TBL] [Abstract][Full Text] [Related]
22. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Patel S; von Mehren M; Reed DR; Kaiser P; Charlson J; Ryan CW; Rushing D; Livingston M; Singh A; Seth R; Forscher C; D'Amato G; Chawla SP; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Demetri GD
Cancer; 2019 Aug; 125(15):2610-2620. PubMed ID: 31173362
[TBL] [Abstract][Full Text] [Related]
23. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
Pérez-Garcia J; Cortés J; Metzger Filho O
Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
[TBL] [Abstract][Full Text] [Related]
26. Pharmacotherapy for liposarcoma: current and emerging synthetic treatments.
Chamberlain F; Benson C; Thway K; Huang P; Jones RL; Gennatas S
Future Oncol; 2021 Jul; 17(20):2659-2670. PubMed ID: 33880964
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
[TBL] [Abstract][Full Text] [Related]
28. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Kaufman PA; Awada A; Twelves C; Yelle L; Perez EA; Velikova G; Olivo MS; He Y; Dutcus CE; Cortes J
J Clin Oncol; 2015 Feb; 33(6):594-601. PubMed ID: 25605862
[TBL] [Abstract][Full Text] [Related]
29. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
30. Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.
Sabatier R; Diéras V; Pivot X; Brain E; Roché H; Extra JM; Monneur A; Provansal M; Tarpin C; Bertucci F; Viens P; Zemmour C; Gonçalves A
Cancer Res Treat; 2018 Oct; 50(4):1226-1237. PubMed ID: 29281873
[TBL] [Abstract][Full Text] [Related]
31. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J; O'Shaughnessy J; Loesch D; Blum JL; Vahdat LT; Petrakova K; Chollet P; Manikas A; Diéras V; Delozier T; Vladimirov V; Cardoso F; Koh H; Bougnoux P; Dutcus CE; Seegobin S; Mir D; Meneses N; Wanders J; Twelves C;
Lancet; 2011 Mar; 377(9769):914-23. PubMed ID: 21376385
[TBL] [Abstract][Full Text] [Related]
32. A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma.
Chen TW; Hsu CL; Hong RL; Lee JC; Chang K; Yu CW; Chen SC; Guo JC; Chen ML; Hsu MC; Kung TF; Cheng AL; Yen CC
Clin Cancer Res; 2022 Dec; 28(23):5058-5065. PubMed ID: 36129471
[TBL] [Abstract][Full Text] [Related]
33. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
[TBL] [Abstract][Full Text] [Related]
34. Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma.
Kim CG; Sim NS; Kim JE; Yun KH; Lee YH; Kim SH; Baek W; Han YD; Kim SK; Kim JH; Koh YW; Jung I; Shin SJ; Rha SY; Ahn JH; Kim HS
Clin Cancer Res; 2022 Aug; 28(15):3225-3234. PubMed ID: 35583824
[TBL] [Abstract][Full Text] [Related]
35. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
36. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
[TBL] [Abstract][Full Text] [Related]
37. Dedifferentiated liposarcoma: when eribulin can make the difference.
Sbrana A; Paolieri F; Bloise F; Manacorda S; Nuzzo A; Sammarco E; Galli L; Falcone A
Future Oncol; 2020 Jan; 16(1s):21-24. PubMed ID: 31872768
[TBL] [Abstract][Full Text] [Related]
38. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
Yuan P; Hu X; Sun T; Li W; Zhang Q; Cui S; Cheng Y; Ouyang Q; Wang X; Chen Z; Hiraiwa M; Saito K; Funasaka S; Xu B
Eur J Cancer; 2019 May; 112():57-65. PubMed ID: 30928806
[TBL] [Abstract][Full Text] [Related]
39. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
